CHEManager has published an article “Artificial Intelligence for New Drug Design” elucidating our journey, our drivers, and most importantly, our commitment to drug discovery Artificial Intelligence for Drug DiscoveryDownload ...
The first annual Iktos conference ‘AI for de novo drug design’, aimed to bring together leading scientists and researchers from industry and academia around the globe, to share their experiences, research, and perspectives about all aspects of Artificial Intelligence (AI) in drug design and retrosynthesis. ...
Iktos team will be at the upcoming GGMM - SFCI congress in Lille, France between September 29th - October 1st 2021. Iktos scientific and technical team will be delivering the following presentations and posters: Brice Hoffmann will be delivering a talk entitled “Structure-guided de novo drug design...
This article has been written by Nicolas Drizard from Iktos, the work presented is a team effort by Nawfal Tachfine, Maoussi Lhuillier-Akakpo, Brice Hoffmann, Nicolas Drizard and Nicolas Do Huu. Data Center - Photo by Tanner Boriack on Unsplash The MELLODDY project provides a unique platform for...
Iktos’s AI technology, based on deep generative models, helps bring speed and efficiency to the drug discovery process. Iktos’ technology automatically designs virtual novel molecules that have all of the characteristics of a successful drug molecule. Iktos AI is the first company to release user-friendly and...
